Latest news
Swiss-based non-profit GARDP supports the development of Debiopharm’s new potential treatment for gonorrhoea
Vulgaroo remporte le 9e Challenge qualité de vie du patient avec un prix de 25’000 francs suisse
CARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae Infections
Debiopharm to Showcase Research Results of Their First-In-Class Anti-Staphylococcal Program at IDWeek 2024 in Los Angeles
Debiopharm Recognizes Groundbreaking Japanese Cancer Research During the 83rd Annual Meeting of the Japanese Cancer Association
Debiopharm and WhiteLab Genomics announce a collaboration to advance drug target and design in Oncology
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-Based Radiopharmaceutical Programs Targeting Solid Tumors
Debiopharm pose la première pierre de son nouveau bâtiment pouvant accueillir jusqu’à 300 collaborateurs tout en sortant des énergies fossilles…